Mothers against decapentaplegic homolog 2 mRNA (SMAD2 mRNA)

Mothers against decapentaplegic homolog 2 (SMAD2) mRNA is the transcript responsible for the synthesis of the SMAD2 protein, a pivotal mediator in the transforming growth factor-beta (TGF-beta) signaling superfamily. Following the activation of TGF-beta type I receptors, the encoded SMAD2 protein undergoes phosphorylation, enabling it to form a heteromeric complex with SMAD4 and translocate into the nucleus to modulate the expression of a wide array of genes involved in cell growth, differentiation, and development (UniProt: Q15796). Pathologically, overactive SMAD2 signaling is a hallmark of various fibrotic disorders and advanced-stage cancers, where it promotes the epithelial-mesenchymal transition (EMT) and contributes to an immunosuppressive tumor microenvironment (PubMed: 29129758). Therapeutic strategies targeting SMAD2 mRNA, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), aim to reduce the pool of available protein to dampen these pathological processes (PubMed: 25650518). A significant challenge in targeting this molecule is the dual role of the TGF-beta pathway, which acts as a tumor suppressor in early stages of cancer but shifts to a pro-oncogenic role in later stages, necessitating careful patient selection and timing of intervention (PubMed: 28232568).

Other names

SMAD family member 2 mRNAMADH2 mRNAMADR2 mRNAJV18-1 mRNAhMAD-2 mRNA

RNA interference or RNase H-mediated degradation of mRNA to prevent protein translation